Cytometryb Clin News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Cytometryb clin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Cytometryb Clin Today - Breaking & Trending Today

Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells

Tiragolumab, an anti-TIGIT antibody with an active IgG1κ Fc, demonstrated improved outcomes in the phase 2 CITYSCAPE trial (ClinicalTrials.gov: NCT03563716 ) when combined with atezolizumab (anti-PD-L1) versus atezolizumab alone1. However, there remains little consensus on the mechanism(s) of response with this combination2. Here we find that a high baseline of intratumoural macrophages and regulatory T cells is associated with better outcomes in patients treated with atezolizumab plus tiragolumab but not with atezolizumab alone. Serum sample analysis revealed that macrophage activation is associated with a clinical benefit in patients who received the combination treatment. In mouse tumour models, tiragolumab surrogate antibodies inflamed tumour-associated macrophages, monocytes and dendritic cells through Fcγ receptors (FcγR), in turn driving anti-tumour CD8+ T cells from an exhausted effector-like state to a more memory-like state. These results reveal a mechanism of ....

South Korea , Cytometryb Clin , Laboratory For Functional Epigenetics , Cancer Biol , Cancer Ther , Molecular Signatures Database , Proteome Res , Acids Res , Functional Epigenetics ,